New study is the first to characterize pegloticase use in the dialysis population.
Lack of timely referrals to nephrologists contribute to racial and ethnic disparities in kidney disease care.
Men who take 5-alpha-reductase inhibitors while on active surveillance for prostate cancer are less likely to experience cancer progression, according to a new study
In a study, patients who experienced hyperkalemia while on a renin-angiotensin-aldosterone-system inhibitor had the lowest 1-year risk of recurrent hyperkalemia when the medication was discontinued.
Black men with metastatic hormone-sensitive prostate cancer may have better outcomes if they receive enzalutamide rather than bicalutamide in combination with androgen deprivation therapy, data from a phase 2 trial suggests.
In a study, statin use was associated with a 36% decreased risk for death among men initiating androgen deprivation therapy for recurrent prostate cancer following primary or salvage radiation therapy.
Difelikefalin, an investigational intravenous drug, improved moderate to severe itching compared with placebo in patients on hemodialysis, according to phase 3 trial results.
In the BETonMACE trial, CKD patients with type 2 diabetes who recently experienced acute coronary syndrome who received apabetalone had a significant 50% reduction in the risk for major cardiovascular events compared with placebo.
Pooled analyses from 2 clinical trials show that voclosporin, a novel calcineurin inhibitor, is safe and effective in managing lupus nephritis.
Finerenone vs placebo added to standard therapy was associated with a significant 18% reduction in the risk for major adverse kidney events in patients with both chronic kidney disease and type 2 diabetes mellitus.
